$AEON Biopharma (AEON.US)$ NEWS AEON Biopharma Announces Pre...
NEWS
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
AEON Biopharma announced that the preliminary results from the Phase 2 trial with ABP-450 for chronic migraine prevention did not meet the primary endpoint of mean reduction in monthly migraine days. The trial showed no statistical significance in reduction compared to placebo, leading to the company initiating cash preservation measures and reviewing strategic options.
The Phase 2 trial with ABP-450 for chronic migraine prevention did not meet the primary endpoint of mean reduction in monthly migraine days. The trial did not show statistical significance in reduction compared to placebo, raising concerns about the drug's efficacy and future development.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
590Followers
67Following
3748Visitors
Follow
Stock_Drift : And you can buy it for a song right now, too.